Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
TGFB1 7040 DOXORUBICIN CHEMBL53463 NCI 12956904
TGFB1 7040 GENISTEIN CHEMBL44 NCI 12580099
TGFB1 7040 HYDROGEN PEROXIDE CHEMBL71595 NCI 9722602
TGFB1 7040 INOSITOL CHEMBL1222251 NCI 8013389
TGFB1 7040 PIOGLITAZONE CHEMBL595 NCI 17407709
TGFB1 7040 TRETINOIN CHEMBL38 NCI 8940178
TGFB1 7040 STREPTOZOTOCIN CHEMBL1651906 NCI 17968528
TGFB1 7040 TOREMIFENE CHEMBL1655 NCI 12476040
TGFB1 7040 TRIAMCINOLONE CHEMBL1451 NCI 12174062
TGFB1 7040 GLATIRAMER ACETATE CHEMBL1201507 PharmGKB
TGFB1 7040 METELIMUMAB CHEMBL2108431 inhibitor ChemblInteractions
TGFB1 7040 AMIFOSTINE CHEMBL1006 NCI 12005544
TGFB1 7040 HYDROCORTISONE CHEMBL389621 NCI 7895901
TGFB1 7040 TAMOXIFEN CHEMBL83 NCI 8019941
TGFB1 7040 FRESOLIMUMAB CHEMBL1743022 inhibitor, antibody TALC, ChemblInteractions
TGFB1 7040 LY-2382770 CHEMBL2109585 inhibitor ChemblInteractions
TGFB1 7040 HYALURONIDASE (HUMAN RECOMBINANT) CHEMBL1201718 Inhibitor DrugBank 7648625, 9435505, 11327694, 9850732
TGFB1 7040 ISOTRETINOIN CHEMBL547 NCI 9815590
TGFB1 7040 ETOPOSIDE CHEMBL44657 NCI 16002781
TGFB1 7040 GALLIUM NITRATE CHEMBL1200983 NCI 8381250
TGFB1 7040 INTERFERON ALFA-2B CHEMBL1201558 NCI 12567763
TGFB1 7040 PIRFENIDONE CHEMBL1256391 NCI 12907346
TGFB1 7040 TESTOSTERONE CHEMBL386630 NCI 9288184
TGFB1 7040 ATENOLOL CHEMBL24 NCI 15049387
TGFB1 7040 ETRETINATE CHEMBL464 NCI 8940178
TGFB1 7040 FENRETINIDE CHEMBL7301 NCI 8993839
TGFB1 7040 RAMIPRIL CHEMBL1168 NCI 15716710
TGFB1 7040 CLADRIBINE CHEMBL1619 NCI 12097998
TGFB1 7040 VITAMIN E CHEMBL47 NCI 9608545, 1505665
TGFB1 7040 ISOFLAVONE CHEMBL366460 NCI 15195125
TGFB1 7040 NICOTINE CHEMBL3 NCI 10198208
TGFB1 7040 ESTRADIOL CHEMBL135 NCI 11498938
TGFB1 7040 EMODIN CHEMBL289277 NCI 11887862
TGFB1 7040 VERAPAMIL CHEMBL6966 NCI 16975733
TGFB1 7040 MELATONIN CHEMBL45 NCI 9649124
TGFB1 7040 GOSSYPOL CHEMBL51483 NCI 15015581
TGFB1 7040 IDOXURIDINE CHEMBL788 NCI 1313063

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
TGFB1 rs1800471 CG adalimumab efficacy no No correlation was seen between genotype and response to anti-TNFalpha treatment. Genotype CG is not associated with response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotype GG. 22129793 982047048
TGFB1 rs1800470 AG rituximab efficacy yes Patients with the AG genotype were more likely to be classified as "responders" to treatment, as compared to those with the AA genotype. "Responders" had a post-rituximab disease activity score (DAS28) of lower than 5.1 and a DAS28 variation between baseline and post-treatment higher than 0.6. Combination with rs1800471 CG genotype led to an even higher probability of responding to treatment, as compared to the AA genotype and rs1800471 GG genotype combined. Please note alleles have been complemented to the plus chromosomal strand. Genotype AG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA. 22129793 982047038
TGFB1 rs1800471 CG rituximab efficacy yes Patients with the CG genotype were more likely to be classified as "responders" to treatment, as compared to those with the GG genotype. "Responders" had a post-rituximab disease activity score (DAS28) of lower than 5.1 and a DAS28 variation between baseline and post-treatment higher than 0.6. Combination with rs1800470 AG genotype led to an even higher probability of responding to treatment, as compared to the GG genotype and rs1800470 AA genotype combined. Genotype CG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype GG. 22129793 982047043
TGFB1 rs1800471 CG etanercept efficacy yes When combined with the IL1RN VNTR in intron 2, A2 allele (no rsID available). Those with the CG-A2 positive combined genotype were more likely to be non-responders to treatment, as compared to those with any other combination of genotypes. However, no significant difference in genotype frequencies was seen between responders and non-responders when considering the rs1800471 SNP or IL1RN VNTR alone. Responders defined using the American College of Rheumatology (ACR) response criteria and response criteria based on the modified disease activity score (DAS)28 index. Non-responders failed to fulfill both these criteria. Genotype CG is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype GG. 12759288 1444668201
TGFB1 rs1800469 A glatiramer acetate efficacy yes Significant only when also combined with the HLA-DRB1*15 allele. Risk of not responding to the drug was significantly increased in individuals carrying this allele combination. This risk was further increased in individuals with the HLA-DRB1*15-rs1800469 A-rs333 del allele combination and HLA-DRB1*15-rs1800469 A-rs333 del-rs1012335 G allele combination. Allele A is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G. 22111603 827823495